Loading... Please wait... Loading... Please wait...
| Reporting Date | Major Shareholder Name | Shares Held | Market Value | Change in Shares | Ownership |
|---|---|---|---|---|---|
| 05/15/2024 | BVF INC/IL | 5.75 M | $1.04 M | 0.00% | 15.05% |
| 05/15/2024 | ARMISTICE CAPITAL, LLC | 2.17 M | $390,960 | 100.00% | 5.69% |
| 05/13/2024 | RENAISSANCE TECHNOLOGIES LLC | 179,577 | $32,000 | 1,316.56% | 0.47% |
| 05/13/2024 | XTX TOPCO LTD | 25,594 | $4,653 | 100.00% | 0.07% |
| 05/15/2024 | CITADEL ADVISORS LLC | 19,183 | $3,487 | 100.00% | 0.05% |
| 05/13/2024 | GEODE CAPITAL MANAGEMENT, LLC | 14,362 | $2,611 | 0.00% | 0.04% |
| 05/15/2024 | BANK OF AMERICA CORP /DE/ | 90 | $16 | 0.00% | 0.00% |
| 05/10/2024 | WELLS FARGO & COMPANY/MN | 0 | $0 | -100.00% | 0.00% |
A. During the previous two years, 9 institutional investors and hedge funds held shares of NLS Pharmaceutics AG. The most heavily invested institutionals were:
BVF INC/IL: 5.75 M
ARMISTICE CAPITAL, LLC: 2.17 M
RENAISSANCE TECHNOLOGIES LLC: 179,577
XTX Topco Ltd: 25,594
CITADEL ADVISORS LLC: 19,183
GEODE CAPITAL MANAGEMENT, LLC: 14,362
A. 21.37% of NLS Pharmaceutics AG stock is owned by institutional investors.
A. Institutional investors have bought a total of 8.17 M shares in the last 24 months. This purchase volume represents approximately $1.57 M in transactions.
